Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal Phase III Study of Cyclotron-produced Tc-99m Pertechnetate (CTC) Compared to Generator-produced Tc-99m Pertechnetate (G-PERT) in Subjects With Thyroid Disorders

NCT02980679 is registered in ClinicalTrials.gov with University of Alberta as lead sponsor.

NCT NCT02980679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02980679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal Phase III Study of Cyclotron-produced Tc-99m Pertechnetate (CTC) Compared to Generator-produced Tc-99m Pertechnetate (G-PERT) in Subjects With Thyroid Disorders
Lead sponsor
University of Alberta
Phase
Phase 3
Overall status
Completed
Start date
March 3, 2017
Completion date
February 25, 2019
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid gland diseases